

Study Authors & Year	% of patients with migraine elimination (N)	% of patients with migraine improvement (N)
Guyuron et al. 2000	Aura-group : 40% (4/10) Non-aura group : 38% (11/29) Overall: 38.5% (15/39)	Aura-group : 70% (7/10) Non-aura group : 82.8% (24/29) Overall: 79.5% (31/39)
Guyuron et al. 2002	45.5% (10/22)	95.5 % (21/22)
Dirnberger & Becker 2004	28.3% (17/60)	68.3 % (41/60)
Bearden & Anderson 2005	58% (7/12)	100% (12/12)
Guyuron et al. 2005	Frontal: 63.8 % (51/80) Temporal: 63.4 % (45/71) Occipital: 61.8 % (21/34) Nasal: 33.9 % (21/62) Overall: 34.8 % (31/89)	Frontal: 98.8% (79/80) Temporal: 98.6% (70/71) Occipital: 100% (34/34) Nasal: 88.7% (55/62) Overall: 92.1% (82/89)
Poggi et al. 2008	16.7 % (3/18)	88.9 % (16/18)
Ducic et al. 2009	35% (72/206)	80.5 % (166/206)
Guyuron et al. 2009	57.1% (28/49)	83.7 % (41/49)
Guyuron et al. 2011	29% (20/69)	88.4% (61/69)
Janis et al. 2011	Frontal: 35% (7/20) Temporal: 52.6% (10/19) Occipital: 56.3% (9/16) Nasal: 62.5% (5/8) Overall: 8.3% (2/24)	Frontal: 85% (17/20) Temporal: 89.5% (17/19) Occipital: 93.8% (15/16) Nasal: 100% (8/8) Overall: 79.2% (19/24)
Larson et al. 2011	39.1% (66/169)	78.7% (133/169)
Liu et al. 2012	35.2% (118/335)	BTA: 84% (207/245) Non-BTA: 80% (72/90) Overall: 83.3% (279/335)
Liu et al. 2012	67% (128/191)	86.6%
Chimielewski et al. 2013	OAR: 38.2% (21/55) Control: 64.3% (74/115) Overall: 55.9% (95/170)	OAR: 80% (44/55) Control: 91.3% (105/115) Overall: 87.6% (149/170)
Lee et al. 2013	TON-R : 26% (29/111) TON-NR : 29% (34/118) Overall : 27.5% (63/229)	TON-R : 80% (89/111) TON-NR : 81% (96/118) Overall : 80.8% (185/229)
Lee et al. 2013	BTA success group: 39.5% (53/144) BTA failure group: 27.2% (12/44) Overall: 34.6% (65/188)	BTA success group: 90.3% (130/144) BTA failure group: 72.7% (32/44) Overall: 86.2% (162/188)
Adenuga et al. 2014	36.6% (41/112)	86.6% (97/112)
Caruana et al. 2014	40% (8/20)	85% (17/20)
Gfrerer et al. 2014	46.5% (20/43)	90.7% (39/43)
Kurlander et al. 2014	55% (54/99)	85% (84/99)
Guyuron et al. 2015	55% (21/38 OR sites)	89% (34/38 OR sites)
Guyuron et al. 2015	36% (5/14)	NR
Raposio & Caruana 2015	6 months: 39.5% (17/43) 2 years: 33.3% (5/15)	6 months: 81.4% (35/43) 2 years: 93.3% (14/15)
Kurlander et al. 2016	57% (76/134)	86% (115/134)
Lin et al. 2016	22.2% (2/9)	88.9% (8/9)
Omranifard et al. 2016	36% (9/25)	76% (19/25)
Peled et al. 2016	37% (7/19)	84.2% (16/19)
Ascha et al. 2017	52% (101/195)	82% (160/195)
Lee et al. 2017	NR	74.5% (73/98)
Raposio & Caruana 2017	69.2% (9/13)	92.3% (12/13)

Jose et al. 2018	46.7% (14/30)	93.3% (28/30)
Afifi et al. 2019	NR	92% (65/71)
Gfrerer et al. 2019	NR	81.9 % (68/83)
Raposio et al. 2019	GON and/or LON: 86.6% (68/78) OAL: 90% (50/56) NTSM: 76% (17/22) Overall: 86.5% (135/156)	GON and/or LON: 94.9% (73/78) OAL: 95.5% (53/56) NTSM: 91% (20/22) Overall: 93.6% (146/156)
Raposio & Simonacci 2020	62%	94%